R. Abraham

发表

Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (SUVN-911): A Novel, Potent, Selective and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2020, Journal of medicinal chemistry.

Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.

R. Nirogi, M. Rasheed, Sugin Lal Jabaris, 2011, European journal of pharmacology.

α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.

R. Nirogi, P. Jayarajan, R. Abraham, 2013, European journal of pharmacology.

Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2012, Brain Research.

Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2022, Psychopharmacology.

Prognostic Utility of Tumor-Infiltrating Lymphocytes in Noncolorectal Gastrointestinal Malignancies

U. Khan, A. Hamza, M. Khurram, 2018, International journal of surgical pathology.

Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders

R. Nirogi, G. Bhyrapuneni, Arunkumar Manoharan, 2021, Journal of psychopharmacology.

SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2019, Behavioural pharmacology.

Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2016, European journal of medicinal chemistry.

Safety of percutaneous transfemoral coronary and peripheral procedures via aortofemoral synthetic vascular grafts.

W. O’Neill, S. Dixon, J. Kahn, 2005, The American journal of cardiology.

Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2023, Biomolecules.

Role of glutamate and advantages of combining memantine with a 5HT_6 ligand in a model of depression

R. Nirogi, A. Shinde, R. Abraham, 2014, Pharmacological reports : PR.

Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2021, Journal of medicinal chemistry.

A Case of Lymphomatoid Granulomatosis in a Lymph Node with Unique Clinical and Histopathologic Features

R. Abraham, D. Patel, R. Rinehart, 2022, The American journal of case reports.

Therapeutic Potential of 5-HT6 Antagonist SB399885 in Traumatic Stress Disorder

R. Nirogi, A. Shinde, V. Benade, 2014, Drug Research.

Aripiprazole in an Animal Model of Chronic Alcohol Consumption and Dopamine D2 Receptor Occupancy in Rats

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2013, The American journal of drug and alcohol abuse.

Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2022, International journal of geriatric psychiatry.

Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2023, European journal of pharmacology.

Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects.

R. Nirogi, A. Shinde, R. Abraham, 2015, Canadian journal of physiology and pharmacology.

SUVN-502, POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST: PROOF-OF-CONCEPT STUDY DESIGN IN MODERATE ALZHEIMER’S DISEASE PATIENTS

R. Nirogi, K. Mudigonda, A. Shinde, 2016, Alzheimer's & Dementia.

Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N₁-arylsulfonyl indole derivatives as 5-HT₆ receptor ligands.

R. Nirogi, V. Kandikere, M. Khagga, 2012, Bioorganic & medicinal chemistry letters.

Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Hits and misses with animal models of narcolepsy and the implications for drug discovery

R. Nirogi, V. Goyal, V. Benade, 2024, Expert opinion on drug discovery.

Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.

R. Nirogi, M. Rasheed, Sugin Lal Jabaris, 2011, European journal of pharmacology.